137 related articles for article (PubMed ID: 21684584)
1. Differential expression patterns of CXCR3 variants and corresponding CXC chemokines in clear cell ovarian cancers and endometriosis.
Furuya M; Yoneyama T; Miyagi E; Tanaka R; Nagahama K; Miyagi Y; Nagashima Y; Hirahara F; Inayama Y; Aoki I
Gynecol Oncol; 2011 Sep; 122(3):648-55. PubMed ID: 21684584
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis.
Furuya M; Suyama T; Usui H; Kasuya Y; Nishiyama M; Tanaka N; Ishiwata I; Nagai Y; Shozu M; Kimura S
Hum Pathol; 2007 Nov; 38(11):1676-87. PubMed ID: 17707463
[TBL] [Abstract][Full Text] [Related]
3. Impaired CXCL4 expression in tumor-associated macrophages (TAMs) of ovarian cancers arising in endometriosis.
Furuya M; Tanaka R; Miyagi E; Kami D; Nagahama K; Miyagi Y; Nagashima Y; Hirahara F; Inayama Y; Aoki I
Cancer Biol Ther; 2012 Jun; 13(8):671-80. PubMed ID: 22555803
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma.
Suyama T; Furuya M; Nishiyama M; Kasuya Y; Kimura S; Ichikawa T; Ueda T; Nikaido T; Ito H; Ishikura H
Cancer; 2005 Jan; 103(2):258-67. PubMed ID: 15578685
[TBL] [Abstract][Full Text] [Related]
5. CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production.
Romagnani P; Maggi L; Mazzinghi B; Cosmi L; Lasagni L; Liotta F; Lazzeri E; Angeli R; Rotondi M; Filì L; Parronchi P; Serio M; Maggi E; Romagnani S; Annunziato F
J Allergy Clin Immunol; 2005 Dec; 116(6):1372-9. PubMed ID: 16337473
[TBL] [Abstract][Full Text] [Related]
6. Expression of CXCL4 in microglia in vitro and in vivo and its possible signaling through CXCR3.
de Jong EK; de Haas AH; Brouwer N; van Weering HR; Hensens M; Bechmann I; Pratley P; Wesseling E; Boddeke HW; Biber K
J Neurochem; 2008 Jun; 105(5):1726-36. PubMed ID: 18248618
[TBL] [Abstract][Full Text] [Related]
7. Expression of interferon-gamma- inducible protein-10 and its receptor CXCR3 in chronic pancreatitis.
Singh L; Bakshi DK; Majumdar S; Vasishta RK; Arora SK; Wig JD
Pancreatology; 2007; 7(5-6):479-90. PubMed ID: 17912012
[TBL] [Abstract][Full Text] [Related]
8. Analysis of CXCR3 and atypical variant expression and signalling in human T lymphocytes.
Korniejewska A; Watson M; Ward S
Methods Mol Biol; 2010; 616():125-47. PubMed ID: 20379873
[TBL] [Abstract][Full Text] [Related]
9. CXC Chemokine Receptor 3 Alternative Splice Variants Selectively Activate Different Signaling Pathways.
Berchiche YA; Sakmar TP
Mol Pharmacol; 2016 Oct; 90(4):483-95. PubMed ID: 27512119
[TBL] [Abstract][Full Text] [Related]
10. CXCR3-B expression correlates with tumor necrosis extension in renal cell carcinoma.
Gacci M; Serni S; Lapini A; Vittori G; Alessandrini M; Nesi G; Palli D; Carini M
J Urol; 2009 Feb; 181(2):843-8. PubMed ID: 19095263
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro.
Helbig KJ; Ruszkiewicz A; Lanford RE; Berzsenyi MD; Harley HA; McColl SR; Beard MR
J Virol; 2009 Jan; 83(2):836-46. PubMed ID: 18987152
[TBL] [Abstract][Full Text] [Related]
12. Expression of a splice variant of CXCR3 in Crohn's disease patients; indication for a lymphocyte--epithelial cell interaction.
Manousou P; Kolios G; Drygiannakis I; Pyrovolaki K; Bourikas L; Papadaki HA; Kouroumalis E
J Gastroenterol Hepatol; 2008 Dec; 23(12):1823-33. PubMed ID: 18761554
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease.
Kao J; Kobashigawa J; Fishbein MC; MacLellan WR; Burdick MD; Belperio JA; Strieter RM
Circulation; 2003 Apr; 107(15):1958-61. PubMed ID: 12695288
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist.
Heise CE; Pahuja A; Hudson SC; Mistry MS; Putnam AL; Gross MM; Gottlieb PA; Wade WS; Kiankarimi M; Schwarz D; Crowe P; Zlotnik A; Alleva DG
J Pharmacol Exp Ther; 2005 Jun; 313(3):1263-71. PubMed ID: 15761110
[TBL] [Abstract][Full Text] [Related]
15. CXCR3 ligands in disease and therapy.
Van Raemdonck K; Van den Steen PE; Liekens S; Van Damme J; Struyf S
Cytokine Growth Factor Rev; 2015 Jun; 26(3):311-27. PubMed ID: 25498524
[TBL] [Abstract][Full Text] [Related]
16. Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes.
Korniejewska A; McKnight AJ; Johnson Z; Watson ML; Ward SG
Immunology; 2011 Apr; 132(4):503-15. PubMed ID: 21255008
[TBL] [Abstract][Full Text] [Related]
17. Functional Analysis of CXCR3 Splicing Variants and Their Ligands Using NanoBiT-Based Molecular Interaction Assays.
Nguyen HT; Hurh S; Nguyen LP; Nguyen TU; Park HK; Seong JY; Lee CS; Ham BJ; Hwang JI
Mol Cells; 2023 May; 46(5):281-297. PubMed ID: 36799104
[TBL] [Abstract][Full Text] [Related]
18. Disparate roles of CXCR3A and CXCR3B in regulating progressive properties of colorectal cancer cells.
Li H; Rong S; Chen C; Fan Y; Chen T; Wang Y; Chen D; Yang C; Yang J
Mol Carcinog; 2019 Feb; 58(2):171-184. PubMed ID: 30302818
[TBL] [Abstract][Full Text] [Related]
19. CXCR3 is involved in tubulointerstitial injury in human glomerulonephritis.
Segerer S; Banas B; Wörnle M; Schmid H; Cohen CD; Kretzler M; Mack M; Kiss E; Nelson PJ; Schlöndorff D; Gröne HJ
Am J Pathol; 2004 Feb; 164(2):635-49. PubMed ID: 14742268
[TBL] [Abstract][Full Text] [Related]
20. Neem leaf glycoprotein restores the impaired chemotactic activity of peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients by maintaining CXCR3/CXCL10 balance.
Chakraborty K; Bose A; Pal S; Sarkar K; Goswami S; Ghosh D; Laskar S; Chattopadhyay U; Baral R
Int Immunopharmacol; 2008 Feb; 8(2):330-40. PubMed ID: 18182249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
